Where I see patients (1)
My reviews
Selected research
-
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC).
NPJ breast cancer
-
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma.
Cancer research
-
Association of lower tumor mutation burden with rapid local progression in patients with brain metastases.
Journal of neurosurgery
Clinical trials
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
rwPFS is defined as the amount of time that elapses between the initiation of ADC1 therapy until the patient experiences disease progression, initiates subsequent anti-cancer therapy, completes study participation, or experiences ...
Recruiting
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast C...
Objective response rate (ORR) is defined as the proportion of participants who experience complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR and corresponding t...
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) i...
IBCFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral ...
Recruiting
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pe...
Evaluate the ability of tucatinib in combination with trastuzumab/pertuzumab or TDM-1 to prolong intracranial progression free survival (PFS) in patients compared to historical controls. PFS is defined as the time from the day of ...
Recruiting
5.0